In a randomized phase 3 trial of patients with metastatic castration-resistant prostate cancer, anit-PD-L1 monoclonal antibody atezolizumab showed a longer progression-free survival in patients with high PD-L1 IC2/3, CD8 expression and established immune gene signatures [5]. The gene discussed is CD274; the disease is prostate carcinoma.